Skip to Main Content

Paper Details

Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
J Mol Diagn
2
2021
Biallelic Loss-of-Function Tumors, CDK12, CDK12 Biallelic, CDK12-WT tumors, CDK12-altered, CDK12-biLOF tumor, CDK12-biLOF tumors, CDK12-monoLOF and, Cancer Types, FTDs, biLOF, biLOF tumors, cancer, cancers, focal tandem duplications, microsatellite instability, mismatch repair deficiency, prostate and ovarian cancers, prostate and ovarian tumors, prostate cancer, tumors
Author NameAffiliation
Joanne XiuInc.
David SpetzlerDepartment of Research and Development, Inc.
Elisabeth I HeathWayne State University/Karmanos Cancer Institute
  • 1 - 3

Datasets

Release 1.2